CVE-2026-50034VulnerabilityPublished 18 Jun 2026

Apollo Pharmacy Blood Glucose Monitoring System APG-01 BT

Affects CISA Apollo PharmacySource GCVE Database

Not known to be exploited.

Data as of 26 Oct 2026, 13:47 UTC

Severity

Unrated

Rated by Threat Radar · No CVSS score from NVD or the CNA

EPSS: 0.2% chance of exploitation in 30 days – higher than 11% of CVEsExploit Prediction Scoring System: the likelihood attackers will use this flaw soon.

Exploitation evidence

Disclosed: evidence found.
CVE published 18 Jun 2026
Detectable: no evidence on record.
No public nuclei template indexed
Weaponised: no evidence on record.
No public exploit code indexed in Metasploit or Exploit-DB
Exploited in the wildExploited: no evidence on record.
Not in CISA KEV and no source reports exploitation
Observed by OffSeq MirageSeen by Mirage: no evidence on record.
No attack traffic recorded by OffSeq Mirage sensors

A missing step is not evidence of safety. Sources: cve.org (opens in a new tab), the Metasploit, Exploit-DB and nuclei-templates index as of 26 Oct 2026.

Disclosed: The CVE record is public on cve.org. Its publication is t = 0.
Detectable: A public nuclei template can find exposed instances, for defenders and attackers alike.
Weaponised: Public exploit code exists in Metasploit or Exploit-DB, or CISA SSVC or the CVSS exploit maturity reports a public proof of concept.
Exploited in the wild: CISA KEV lists it, CISA SSVC rates exploitation active, or a source reports attacks.
Observed by OffSeq Mirage: OffSeq Mirage honeypot sensors recorded attack traffic for this CVE, or found exposed hosts without attack traffic.

Moments are spaced evenly, not to scale; a dashed line marks a gap of six months or more. Deltas count from t = 0. Sources that give only a date (CISA KEV, Exploit-DB, or a time of exactly 00:00Z) read “same day” rather than hours. Metasploit modules carry the flaw’s disclosure date, not their release date, and nuclei templates carry no date, so both appear above but not on the timeline.

cisa

What to do

Affected software

Product	Affected	Fixed in
CISA Apollo Pharmacy	Affected =0x0110_v1.1.0	Fixed in–

Description

CISA recommends users take defensive measures to minimize the risk of exploitation of these vulnerabilities.

CWE-319Cleartext Transmission of Sensitive Information (opens in a new tab)
Base weaknessLikelihood of exploit: HighOWASP Top 10 A04:2025: Cryptographic Failures (opens in a new tab)
The product transmits sensitive or security-critical data in cleartext in a communication channel that can be sniffed by unauthorized actors.
Architecture and Design
Before transmitting, encrypt the data using reliable, confidentiality-protecting cryptographic protocols.
Implementation
When using web applications with SSL, use SSL for the entire session from login to logout, not just for the initial login page.
Implementation
When designing hardware platforms, ensure that approved encryption algorithms (such as those recommended by NIST) protect paths from security critical data to trusted user applications.
OWASP Cheat Sheets
Transport Layer Protection (opens in a new tab)
TLS Cipher String (opens in a new tab)
User Privacy Protection (opens in a new tab)
Password Storage (opens in a new tab)
Cryptographic Storage (opens in a new tab)
OWASP ASVS 4.0.3
V8.3.1 (opens in a new tab)
V9.2.2 (opens in a new tab)
V1.9.1 (opens in a new tab)
Attack patterns
Session Sidejacking (opens in a new tab)
Harvesting Information via API Event Monitoring (opens in a new tab)
Signature Spoofing by Mixing Signed and Unsigned Content (opens in a new tab)
Sniff Application Code (opens in a new tab)
Interception (opens in a new tab)
From MITRE CWE, MITRE CAPEC and OWASP (Top 10, OpenCRE).
CWE-862Missing Authorization (opens in a new tab)
Class weaknessLikelihood of exploit: HighCWE Top 25 (2025): #4OWASP Top 10 A01:2025: Broken Access Control (opens in a new tab)
The product does not perform an authorization check when an actor attempts to access a resource or perform an action.
Architecture and Design
Divide the product into anonymous, normal, privileged, and administrative areas. Reduce the attack surface by carefully mapping roles with data and functionality. Use role-based access control (RBAC) to enforce the roles at the appropriate boundaries.
Architecture and Design
Ensure that access control checks are performed related to the business logic. These checks may be different than the access control checks that are applied to more generic resources such as files, connections, processes, memory, and database records.
Architecture and Design · Libraries or Frameworks
Use a vetted library or framework that does not allow this weakness to occur or provides constructs that make this weakness easier to avoid.
OWASP Cheat Sheets
Authorization (opens in a new tab)
OWASP ASVS 4.0.3
V8.3.8 (opens in a new tab)
V13.4.2 (opens in a new tab)
V7.2.2 (opens in a new tab)
Attack patterns
Exploitation of Thunderbolt Protection Flaws (opens in a new tab)
From MITRE CWE, MITRE CAPEC and OWASP (Top 10, OpenCRE).

References

Community reviews

Loading reviews…

Exploitation evidence

What to do

Affected software

Description

WeaknessesCWE-319, CWE-862

Technical details

References

Community reviews

Related threats